A study evaluating the efficacy and safety of ¹⁷⁷Lu-PSMA radioligand therapy for treating mCRPC in octogenarians demonstrated that radioligand therapy is safe and effective also in elderly patients. Moreover, patients who have not previously undergone chemotherapy had a better and longer-lasting response both in terms of overall and progression-free survival.

Treatment-emergent grade 3 toxicities were low, supporting the conclusion that ¹⁷⁷Lu-PSMA RLT is a safe and effective option for elderly mCRPC patients.